Volunteer Donate Get Help

In the News

The latest news reports, articles, and stories that may be of importance to leukemia and lymphoma patients, caregivers, and family members.

Choosing a TKI for CML

Published: February 01, 2018

Author: Bryant Furlow

Source: Cancer Therapy Advisor

The BCR-ABL tyrosine kinase inhibitors (TKIs) were an early example of a successful targeted cancer treatment and have dramatically improved outcomes for patients diagnosed with chronic myeloid leukemia (CML ... More >>.

Vaccine Eliminates Cancer Tumors

Published: January 31, 2018

Author: Steve Fisch

Source: Stanford University Medical Center

Ronald Levy and Idit Sagiv-Barfi led the work on a possible cancer treatment that involves injecting two immune-stimulating agents directly into solid tumors. Injecting minute amounts of two immune-stimulati ... More >>.

Stopping Treatment for CML

Published: January 30, 2018

Author: Andrea Greif

Source: Leukemia & Lymphoma Society

When the targeted oral therapy, imatinib (Gleevec) was approved by the U.S. Food & Drug Administration (FDA) in 2001, it revolutionized treatment for patients with chronic myeloid leukemia (CML), turning ... More >>.

Melting Away of Leukemia

Published: January 08, 2018

Source: Cold Spring Harbor Laboratory

Cancer researchers today announced they have developed a way of sideling one of the most dangerous "bad actors" in leukemia. Their approach depends on throwing a molecular wrench into the gears of an importa ... More >>.

Gene Variants Identified

Published: January 04, 2018

Source: St. Jude Children's Research Hospital

Newly identified germline variations in a key tumor suppressor gene predispose individuals to develop leukemia as children and leave them with a 1-in-4 chance of developing a second cancer later. St. Jude Ch ... More >>.

Loophole in CLL Treatment

Published: January 04, 2018

Source: Rockefeller University Press

A team of researchers in Italy and Austria has determined that a drug approved to treat chronic lymphocytic leukemia (CLL) may be less effective in a particular subset of patients. The study, which will be p ... More >>.

AML Study Reports High Reponse Rates

Published: December 11, 2017

Source: M.D. Anderson Cancer Center

Initial findings from a multi-national open label phase study of inhibitory drug therapy for relapsed or refractory acute myeloid leukemia (AML) have demonstrated a complete response in up to 50 percent pati ... More >>.

CAR T Therapy for non-Hodgkin's Lymphoma

Published: December 10, 2017

Source: University of Pennsylvania School of Medicine

In a pair of clinical trials stretching from Philadelphia to Tokyo, the chimeric antigen receptor (CAR) T cell therapy Kymriah demonstrated long-lasting remissions in non-Hodgkin's lymphoma (NHL) patients. R ... More >>.

AML a Risk With PARP Inhibitors

Published: December 05, 2017

Author: Lisa A. Thompson, PharmD, BCOP

Source: Oncology Nurse Advisor

Acute Myeloid Leukemia (AML) has been reported in patients receiving poly (ADP-ribose) polymerase (PARP) inhibitors such as olaparib (Lynparza), rucaparib (Rubraca), and niraparib (Zejula). Warnings about AM ... More >>.

New Cell Therapy for Relapsed Leukemia Patients

Published: November 20, 2017

Source: Stanford University Medical Center

A significant proportion of children and young adults with treatment-resistant B-cell leukemia who participated in a small study achieved remission with the help of a new form of gene therapy, according to r ... More >>.

©2015 Stephanie Robinson Foundation | Privacy Policy